VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
VERTEX PHARMACEUTICALS INC / MA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$501.95+2.21 (+0.44%)
Close on Oct 19, 2026
- Market cap
- $128.10B
- P/E (TTM)
- 29.2
- Dividend yield
- –
Vertex Pharmaceuticals Inc / Ma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Market Cap | $127.23B | $166.30M |
| Enterprise Value | $119.37B | $88.19M |
| PE Ratio | 29.22 | 20.44 |
| PS Ratio | 10.11 | 3.65 |
| PB Ratio | 6.28 | 2.03 |
| P/TBV Ratio | 6.79 | 2.29 |
| P/FCF Ratio | 33.51 | 17.44 |
| P/OCF Ratio | 29.64 | 12.98 |
Enterprise value
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| EV / Sales | 9.48 | 2.51 |
| EV / EBITDA | 23.88 | 14.65 |
| EV / EBIT | 24.99 | 19.00 |
| EV / FCF | 31.45 | 20.86 |
Income (trailing twelve months)
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Revenue | $12.59B | $58.34M |
| Gross Profit | $10.82B | $105.94M |
| Operating Income | $4.78B | -$21.40M |
| Pretax Income | $5.27B | -$14.34M |
| Net Income | $4.41B | -$22.46M |
| EBITDA | $5.00B | -$16.91M |
| EPS (Diluted) | $17.18 | -$0.83 |
Margins
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Gross Margin | 86.0% | 52.9% |
| Operating Margin | 38.0% | -44.0% |
| Pretax Margin | 41.9% | -13.3% |
| Profit Margin | 35.0% | -40.2% |
| EBITDA Margin | 39.7% | -30.2% |
| FCF Margin | 30.2% | -9.27% |
Returns
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Return on Equity (ROE) | 23.5% | -53.2% |
| Return on Assets (ROA) | 17.1% | -40.9% |
| Return on Invested Capital (ROIC) | 34.4% | -32.4% |
| Return on Capital Employed (ROCE) | 20.3% | -38.1% |
Growth
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 10.2% | 5.96% |
| Net Income Growth (YoY) | 21.1% | -35.2% |
| EPS Growth (YoY) | 22.4% | -26.2% |
| FCF Growth (YoY) | 8.47% | 2.34% |
| Revenue Growth (3Y CAGR) | 10.4% | 2.25% |
| Revenue Growth (5Y CAGR) | 14.1% | 6.48% |
| EPS Growth (3Y CAGR) | 6.12% | -0.17% |
| EPS Growth (5Y CAGR) | 8.29% | 3.77% |
Balance sheet
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $7.85B | $61.43M |
| Net Cash (Debt) | $7.85B | $15.35M |
| Net Cash Per Share | $30.98 | $0.66 |
| Equity (Book Value) | $20.25B | $49.09M |
| Book Value Per Share | $79.89 | $1.37 |
| Tangible Book Value | $18.75B | $23.52M |
| Working Capital | $8.61B | $76.81M |
Financial position
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Current Ratio | 3.19 | 3.34 |
| Quick Ratio | 2.54 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Operating Cash Flow | $4.29B | -$12.35M |
| Capital Expenditures | -$496.80M | -$1.08M |
| Free Cash Flow | $3.80B | -$20.22M |
| FCF Per Share | $14.98 | -$0.42 |
Efficiency
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Asset Turnover | 0.49 | 0.39 |
| Inventory Turnover | 1.08 | 2.70 |
| Revenue Per Employee | $20.98K | $404.87K |
| Profits Per Employee | $7.34K | -$703.34K |
| Employee Count | 600,000 | 74 |
Dividends and yields
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Earnings Yield | 3.46% | -23.3% |
| FCF Yield | 2.98% | -8.72% |
| Buyback Yield | 1.58% | -0.59% |
| Shareholder Yield | 1.58% | 0.00% |
Shares
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Shares Outstanding | 253,461,000 | 58,127,000 |
| Shares Change (YoY) | -1.10% | 10.9% |
| Shares Change (QoQ) | -0.32% | 0.54% |
| Float | 252,874,000 | 49,136,700 |
| Shares Held by Insiders | 0.23% | 11.6% |
| Shares Held by Institutions | 95.6% | 59.4% |
Taxes
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Income Tax | $869.30M | $79.87K |
| Effective Tax Rate | 16.5% | 20.6% |
Scores
| Measure | Vertex Pharmaceuticals Inc / Ma | Industry median |
|---|---|---|
| Graham Number | $175.73 | $18.73 |
| Graham Upside | -65.0% | -45.1% |
| Altman Z-Score | 12.85 | -0.22 |
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | -2.18 | -2.62 |
Calculated by StockData from Vertex Pharmaceuticals Inc / Ma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.